LAB

Standard BioTools Inc

Add to Watchlist

Advanced Chart

1.250

+0.02(1.626%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.315

Open

1.280

VWAP

1.30

Vol

599.45K

Mkt Cap

467.18M

Low

1.250

Amount

777.64K

EV/EBITDA(TTM)

Total Shares

370.42M

233.07M

EV/OCF(TTM)

P/S(TTM)

3.79

Standard BioTools Inc. develops, manufactures and sells a diversified range of instrumentation, consumables, and services that help scientists and biomedical researchers. The Company's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The Company works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. It offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

31.20M

-23.52%

-0.020

-58.16%

33.10M

-29.15%

-0.040

-19.03%

30.70M

-31.73%

-0.040

+15.61%

Estimates Revision

The market is revising No Change the revenue expectations for Standard BioTools Inc. (LAB) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 19.05%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-19.23%

In Past 3 Month

Stock Price

Go Up

+19.05%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast LAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LAB is 2.50 USD with a low forecast of 2.50 USD and a high forecast of 2.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.250

Low

2.50

Averages

2.50

High

2.50

Current: 1.250

Low

2.50

Averages

2.50

High

2.50

TD Cowen

Buy

Hold

downgrade

2025-08-13

New

Reason

TD Cowen

Price Target

2025-08-13

New

downgrade

Buy

Hold

Reason

TD Cowen downgraded Standard BioTools to Hold from Buy with a price target of $1.55, down from $1.60, post the Q2 report. The company sees a lower growth outlook for the core business and less visibility following the sale of SomaLogic. The company's core business trends will continue to be challenged amid macro headwinds, the analyst tells investors in a research note.

Keybanc

Paul Knight

Buy

Hold

Downgrades

n/a

2025-02-27

Reason

Keybanc

Paul Knight

Price Target

n/a

2025-02-27

Downgrades

Buy

Hold

Reason

KeyBanc analyst Paul Knight downgraded Standard BioTools to Sector Weight from Overweight without a price target. The company reported preannounced Q4 results with "disappointing" initial 2025 revenue guidance, the analyst tells investors in a research note. The firm says Standard Bio attributed its guidance to the proposed White House National Institutes of Health spending cut that may drive cautious spending for its academic customers. With a "tepid" spending environment and more meaningful commercial revenue from Illumina unlikely to occur until 2026, KeyBanc downgrades the shares.

TD Cowen

Daniel Brennan

Strong Buy

Maintains

$2.75 → $2.5

2024-10-31

Reason

TD Cowen

Daniel Brennan

Price Target

$2.75 → $2.5

2024-10-31

Maintains

Strong Buy

Reason

Reports Q3 revenue $45M, consensus $41M."Powered by Standard BioTools Business System SBS , we focused our third quarter efforts on driving commercial execution and enhancing overall operating efficiency. Our team delivered sequential top-line improvement and a significant reduction in spend," said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. "Last quarter, we announced the acceleration of our anticipated $80 million of merger synergies into 2025, contributing to a 50% improvement in adjusted EBITDA year over year, keeping us on track toward achieving our break-even adjusted EBITDA target in 2026." Mr. Egholm added, "Our focus on operational excellence and profitability is positioning us for sustained value creation once macro pressures ease. At the same time, we're investing in certain growth levers within our leading multi-omics portfolio while actively pursuing strategic M&A to accelerate our mission toward becoming a diversified leader in the life science tools industry."

See All Ratings

Valuation Metrics

The current forward P/E ratio for Standard BioTools Inc (LAB.O) is -9.46, compared to its 5-year average forward P/E of -12.46. For a more detailed relative valuation and DCF analysis to assess Standard BioTools Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-12.46

Current PE

-9.46

Overvalued PE

4.63

Undervalued PE

-29.55

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-7.92

Current EV/EBITDA

-6.16

Overvalued EV/EBITDA

-3.59

Undervalued EV/EBITDA

-12.26

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

2.56

Current PS

3.66

Overvalued PS

3.71

Undervalued PS

1.41

Financials

Annual

Quarterly

FY2025Q2

YoY :

-57.87%

15.67M

Total Revenue

FY2025Q2

YoY :

-29.06%

-29.79M

Operating Profit

FY2025Q2

YoY :

-61.34%

-17.67M

Net Income after Tax

FY2025Q2

YoY :

-25.00%

-0.09

EPS - Diluted

FY2025Q2

YoY :

-44.97%

-22.56M

Free Cash Flow

FY2025Q2

YoY :

-27.73%

28.96

Gross Profit Margin - %

FY2025Q2

YoY :

-8.24%

-112.76

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

57.5K

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

443.0K

USD

Months

3-6

0.0

USD

Months

6-9

5.1M

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

11.5M

Volume

Months

6-9

0.0

Volume

Months

0-12

7.0M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

57.5K

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

443.0K

USD

Months

3-6

0.0

USD

Months

6-9

5.1M

USD

Months

0-12

0.0

USD

Months

LAB News & Events

Events Timeline

2025-08-11 (ET)

2025-08-11

16:13:04

Standard BioTools sees FY25 revenue $165M-$175M, consensus $169.13M

2025-08-11

16:12:17

Standard BioTools reports Q2 EPS (9c), consensus (4c)

2025-08-06 (ET)

2025-08-06

07:28:41

Standard BioTools, Precision Health, Singapore launch proteomic collaboration

News

7.0

06-25Benzinga

FedEx Issues Soft Guidance, Joins Torrid Holdings, Allot And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

8.5

06-23Benzinga

SomaLogic Acquisition Marks Next Step In Illumina's Advanced Biomarker Push

9.5

06-23Benzinga

Kroger Posts Better-Than-Expected Earnings, Joins Couchbase, CarMax And Other Big Stocks Moving Higher On Friday

People Also Watch

Tetra Technologies Inc

Ituran Location and Control Ltd

USANA Health Sciences Inc

International Money Express Inc

FAQ

What is Standard BioTools Inc (LAB) stock price today?

The current price of LAB is 1.25 USD — it has increased 1.63 % in the last trading day.

LAB

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

LAB News & Events

Events Timeline

News

People Also Watch

FAQ

What is Standard BioTools Inc (LAB) stock price today?

What is Standard BioTools Inc (LAB)'s business?

What is the price predicton of LAB Stock?

What is Standard BioTools Inc (LAB)'s revenue for the last quarter?

What is Standard BioTools Inc (LAB)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Standard BioTools Inc (LAB)'s fundamentals?

How many employees does Standard BioTools Inc (LAB). have?

What is Standard BioTools Inc (LAB) market cap?